Endpoints News3 小时
No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al
Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the ...
Endpoints News4 小时
Obe­si­ty drug de­vel­op­ment—still room to grow
Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) quickly reached blockbuster status within their ...